Impact of Additive Use of Olmesartan in Patients with Chronic Heart Failure: The Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients with Stable Heart Failure Using Olmesartan (SUPPORT) Trial - Discussion

American Heart Association Scientific Sessions
Sunday, November 16, 2014

Eric J. Velazquez, MD, FACP, FACC, FASE, FAHA
Professor of Medicine
Director, Cardiac Diagnostic Unit & Echocardiography Laboratories
Asst. Director, Clinical Trials
Duke University Health System & Duke Clinical Research Institute
SUPPORT: Key Features

- Men ~ 75%*
- BP ~ 127/74*
- HR ~ 71*
- NYHA FC II ~ 95%*
- BNP ~ 80*
- Diuretics ~ 56.5%*
- BB ~ 75%*
- ACEi ~ 81%*

- Minimal LTFU
- No change in static BP over time

* ns
SUPPORT: Unknowns

- HF diagnosis - confirmed?
  - Prior HF Hospitalizations
- Study drug adherence?
- Dose achieved?
- Ambulatory blood pressure?
- Incidence of hyperkalemia?
### How does SUPPORT population compare?

<table>
<thead>
<tr>
<th></th>
<th>DIG</th>
<th>CHARM</th>
<th>SENIORS</th>
<th>PEP</th>
<th>I-Preserve</th>
<th>SUPPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>67</td>
<td>67</td>
<td>76</td>
<td>75</td>
<td>72</td>
<td>65</td>
</tr>
<tr>
<td>Women, %</td>
<td>41</td>
<td>40</td>
<td>49</td>
<td>55</td>
<td>60</td>
<td>25</td>
</tr>
<tr>
<td>EF, %</td>
<td>55</td>
<td>54</td>
<td>49</td>
<td>64</td>
<td>59</td>
<td>54</td>
</tr>
<tr>
<td>Prior MI, %</td>
<td>50</td>
<td>44</td>
<td>34</td>
<td>26</td>
<td>23</td>
<td>NA</td>
</tr>
<tr>
<td>IHD, %</td>
<td>56</td>
<td>57</td>
<td>NA</td>
<td>NA</td>
<td>25</td>
<td>46</td>
</tr>
</tbody>
</table>
**SUPPORT Results**

- No improvement overall
  - *Disappointing but not surprising*
- ... with worse renal function
  - *Mechanism unclear*
- ... concerning signals
  - *Numerically higher new DM, strokes, SCDs*
- ... and more adverse clinical events among patients treated with “triple combination”
- ... limited impact on clinical care and/or guidelines